 alternate-day cloprednol therapy prevent bone loss longitudinal double-blind clinical study Osteoporosis serious side effect systemic treatment steroids Cloprednol synthetic glucocorticoid anti-inflammatory potency prednisone calcium nitrogen excretion equipotent doses double-blind study undertaken effects alternate-day cloprednol prednisone therapy bone mineral density patients cloprendol men women years prednisone men women years lung diseases patients asthma men woman years daily beclomethasone control subjects Trabecular total bone density distal tibia radius year special-purpose tomographic system Initial mean trabecular bone density patients cloprednol prednisone normal treatment period year loss radial trabecular bone density mean SEM cloprednol group prednisone group postmenopausal women prednisone cloprednol therapy significant trabecular bone loss control group Loss cortical bone insignificant groups post-menopausal women year alternate-day cloprednol therapy bone loss prednisone therapy equipotent dosages